Latest & greatest articles for spironolactone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on spironolactone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on spironolactone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for spironolactone

21. [Cost-effectiveness of the use of spironolactone in the treatment of chronic heart failure]

[Cost-effectiveness of the use of spironolactone in the treatment of chronic heart failure] Analisis coste-efectividad del uso de espironolactona en el tratamiento de la insuficiencia cardiaca cronica [Cost-effectiveness of the use of spironolactone in the treatment of chronic heart failure] Analisis coste-efectividad del uso de espironolactona en el tratamiento de la insuficiencia cardiaca cronica [Cost-effectiveness of the use of spironolactone in the treatment of chronic heart failure] Soto (...) Alvarez J, Gonzalez Vilchez F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention under examination was spironolactone 25 mg daily as adjunct therapy for the treatment of patients with chronic heart failure (CHF

NHS Economic Evaluation Database.2001

23. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.

Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. BACKGROUND: Hirsutism is the presence of excessive hair growth in women and is an important cosmetic condition often resulting in severe distress. Hirsutism is most often caused by increased production of male sex hormones also known as androgens. It is also affected by increased sensitivity to androgens in the hair follicles, and the secretory glands around the hair follicles, called sebaceous glands (...) . Spironolactone is an antiandrogen and aldosterone antagonist used to treat hirsutism. Since 1978, many studies have been conducted to determine its effectiveness. OBJECTIVES: The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women. SEARCH STRATEGY: All publications of randomised controlled trials of spironolactone versus placebo and/or in combination

Cochrane2000

24. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. 10471456 1999 09 02 1999 09 02 2013 11 21 0028-4793 341 10 1999 Sep 02 The New England journal of medicine N. Engl. J. Med. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. 709-17 Aldosterone is important in the pathophysiology of heart failure. In (...) a doubleblind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an angiotensin-converting-enzyme inhibitor, a loop diuretic, and in most cases digoxin. A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end point was death from all causes. The trial was discontinued early, after a mean follow-up period of 24 months

NEJM1999